Ultragenyx Pharmaceutical Inc (RARE)
42.39
-0.96
(-2.21%)
USD |
NASDAQ |
Apr 19, 16:00
42.39
0.00 (0.00%)
After-Hours: 16:44
Ultragenyx Pharmaceutical Enterprise Value: 2.992B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 2.992B |
| April 17, 2024 | 3.055B |
| April 16, 2024 | 2.906B |
| April 15, 2024 | 2.953B |
| April 12, 2024 | 3.293B |
| April 11, 2024 | 3.597B |
| April 10, 2024 | 3.672B |
| April 09, 2024 | 3.586B |
| April 08, 2024 | 3.559B |
| April 05, 2024 | 3.559B |
| April 04, 2024 | 3.299B |
| April 03, 2024 | 3.299B |
| April 02, 2024 | 3.259B |
| April 01, 2024 | 3.290B |
| March 28, 2024 | 3.267B |
| March 27, 2024 | 3.278B |
| March 26, 2024 | 3.166B |
| March 25, 2024 | 3.162B |
| March 22, 2024 | 3.198B |
| March 21, 2024 | 3.264B |
| March 20, 2024 | 3.293B |
| March 19, 2024 | 3.293B |
| March 18, 2024 | 3.259B |
| March 15, 2024 | 3.323B |
| March 14, 2024 | 3.264B |
| Date | Value |
|---|---|
| March 13, 2024 | 3.420B |
| March 12, 2024 | 3.347B |
| March 11, 2024 | 3.417B |
| March 08, 2024 | 3.583B |
| March 07, 2024 | 3.610B |
| March 06, 2024 | 3.643B |
| March 05, 2024 | 3.661B |
| March 04, 2024 | 3.812B |
| March 01, 2024 | 3.843B |
| February 29, 2024 | 3.681B |
| February 28, 2024 | 3.766B |
| February 27, 2024 | 3.841B |
| February 26, 2024 | 3.560B |
| February 23, 2024 | 3.497B |
| February 22, 2024 | 3.447B |
| February 21, 2024 | 3.390B |
| February 20, 2024 | 3.364B |
| February 16, 2024 | 3.451B |
| February 15, 2024 | 3.232B |
| February 14, 2024 | 3.181B |
| February 13, 2024 | 3.043B |
| February 12, 2024 | 3.270B |
| February 09, 2024 | 3.269B |
| February 08, 2024 | 3.164B |
| February 07, 2024 | 3.103B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.201B
Minimum
Mar 16 2020
10.97B
Maximum
Dec 23 2020
3.691B
Average
3.096B
Median
Enterprise Value Benchmarks
| Corcept Therapeutics Inc | 1.980B |
| Madrigal Pharmaceuticals Inc | 3.910B |
| Sarepta Therapeutics Inc | 10.50B |
| Rocket Pharmaceuticals Inc | 1.748B |
| Apellis Pharmaceuticals Inc | 5.471B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -123.19M |
| Revenue (Quarterly) | 127.39M |
| Total Expenses (Quarterly) | 249.44M |
| EPS Diluted (Quarterly) | -1.52 |
| Gross Profit Margin (Quarterly) | 90.54% |
| Profit Margin (Quarterly) | -96.70% |
| Earnings Yield | -19.65% |
| Normalized Earnings Yield | -19.67 |